Skip to main content
Premium Trial:

Request an Annual Quote

Predicine, CloudHealth Launch Liquid Biopsy Tests in China

NEW YORK (GenomeWeb) – Predicine announced today that its next-generation sequencing-based liquid biopsy diagnostics for lung cancer and prostate cancer are the first tests to launch in China under a co-promotion deal with Shanghai-based CloudHealth Genomics.

In April, the companies announced that they had signed a deal under which CloudHealth will provide clinical genetic testing infrastructure and sequencing capacity in China for Predicine's PrediSeq cell-free DNA NGS cancer diagnostics. 

According to Predicine, its PrediSeq-Lung and PrediSeq-Prostate liquid biopsy tests are the first covered under the partnership, with additional tests for major cancer types planned to launch in China later this year.

The Scan

Tara Pacific Expedition Project Team Finds High Diversity Within Coral Reef Microbiome

In papers appearing in Nature Communications and elsewhere, the team reports on findings from the two-year excursion examining coral reefs.

Study Examines Relationship Between Cellular Metabolism, DNA Damage Repair

A new study in Molecular Systems Biology finds that an antioxidant enzyme shifts from mitochondria to the nucleus as part of the DNA damage response.

Stem Cell Systems Target Metastatic Melanoma in Mouse Model

Researchers in Science Translational Medicine describe a pair of stem cell systems aimed at boosting immune responses against metastatic melanoma in the brain.

Open Pediatric Brain Tumor Atlas Team Introduces Genomic Data Collection, Analytical Tools

A study in Cell Genomics outlines open-source methods being used to analyze and translate whole-genome, exome, and RNA sequence data from the Pediatric Brain Tumor Atlas.